Avenue Therapeutics, Inc. (NASDAQ:ATXI) Short Interest Update

Avenue Therapeutics, Inc. (NASDAQ:ATXI) saw a large growth in short interest during the month of January. As of January 31st, there was short interest totalling 154,900 shares, a growth of 92.2% from the January 15th total of 80,600 shares. Currently, 8.9% of the company’s stock are sold short. Based on an average trading volume of 366,900 shares, the short-interest ratio is presently 0.4 days.

Institutional Investors Weigh In On Avenue Therapeutics

An institutional investor recently bought a new position in Avenue Therapeutics stock. Moss Adams Wealth Advisors LLC acquired a new position in Avenue Therapeutics, Inc. (NASDAQ:ATXI) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 11,000 shares of the company’s stock, valued at approximately $27,000. Moss Adams Wealth Advisors LLC owned approximately 1.17% of Avenue Therapeutics as of its most recent filing with the Securities and Exchange Commission. 17.34% of the stock is owned by hedge funds and other institutional investors.

Avenue Therapeutics Stock Performance

Shares of ATXI opened at $1.36 on Friday. Avenue Therapeutics has a 52 week low of $1.22 and a 52 week high of $15.00. The stock has a 50 day moving average price of $1.70 and a two-hundred day moving average price of $2.13. The firm has a market capitalization of $2.79 million, a P/E ratio of 0.07 and a beta of -0.28.

About Avenue Therapeutics

Avenue Therapeutics, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders.